COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

In Vitro Maturation (IVM) of Human Oocytes (IVM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01550861
Recruitment Status : Active, not recruiting
First Posted : March 12, 2012
Last Update Posted : November 26, 2019
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
The objectives of this study are to evaluate the clinical efficacy of Natural in vitro Fertilization and in vitro maturation.

Condition or disease Intervention/treatment Phase
Infertility Procedure: in vitro maturation Procedure: Polar Body Biopsy with preimplantation genetic screening Not Applicable

Detailed Description:
Collection of one mature egg from a follicle in the ovary without gonadotropin medications (natural cycle IVF) results in low pregnancy rates. One way to improve natural cycle IVF is to combine this procedure with the removal of immature eggs from the ovary and mature these eggs in the laboratory ( in vitro maturation-IVM). The in vitro mature eggs are fertilized and the resultant embryos are cultured using conventional IVF techniques.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: In Vitro Maturation (IVM) of Human Oocytes
Study Start Date : February 2012
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Infertility

Arm Intervention/treatment
Experimental: In vitro Maturation
in vitro maturation of immature oocytes
Procedure: in vitro maturation
Maturation of immature oocytes in the laboratory following oocyte retrieval

Procedure: Polar Body Biopsy with preimplantation genetic screening
Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.

Primary Outcome Measures :
  1. number of oocytes retrieved and embryos generated [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. live birth rate [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 42 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Each subject must be female.
  2. Each subject must have an indication for COH and IVF with or without ICSI.
  3. Each subject must be willing and able to provide written informed consent for the trial
  4. Each subject must be 25 to ≤42 years of age at the time of signing informed consent.
  5. Each subject must have a normal cervical smear result (no atypical or abnormal cells, or in case of atypical squamous or glandular cells, no signs of malignancy; corresponding to Papanicolaou [PAP] I or II) obtained within 12 months prior to signing informed consent must be available

Exclusion Criteria:

  1. Subject with premature ovarian failure
  2. Subject with endocrine abnormalities such as hyperprolactinaemia or thyroid dysfunction
  3. Subject with malformation or absence of uterus
  4. Subject has tested positive for Human Immunodeficiency Virus (HIV) or Hepatitis B (by local laboratory; results obtained within 1 year prior to signing ICF are considered valid).
  5. Subject with contraindication or allergy/hypersensitivity to hCG, estrogen and progesterone

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01550861

Layout table for location information
United States, New York
Center for Reproductive Medicine- Weill Cornell Medical College
New York, New York, United States, 10021
Sponsors and Collaborators
Weill Medical College of Cornell University
Layout table for investigator information
Principal Investigator: Zev Rosenwaks, MD Weill Cornell
Additional Information:
Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University Identifier: NCT01550861    
Other Study ID Numbers: 1201012117
First Posted: March 12, 2012    Key Record Dates
Last Update Posted: November 26, 2019
Last Verified: November 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Weill Medical College of Cornell University:
in vitro maturation (IVM)
in vitro fertilization (IVF)
natural cycle
Additional relevant MeSH terms:
Layout table for MeSH terms
Genital Diseases, Male
Genital Diseases, Female